Doseology Sciences Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher Jackson
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 406-460 Doyle Avenue Kelowna BC Canada V1Y 0C2
- IPO Date
- May 11, 2022
- Website
- doseology.com
- Similar Companies
- Business
- Doseology Sciences Inc. (CSE: MOOD; OTCQB: DOSEF) develops and sells nutraceutical products focused on mental health and wellness through its subsidiary Dose Labs Inc., specializing in functional mushroom supplements including tinctures, powders, and herbal blends targeting cognition, focus, energy, sleep, immunity, and stress relief; the company engineers precision-formulated oral stimulants using biotechnology and advanced delivery systems such as pouches with nootropics, adaptogens, and superfoods derived from 100% mushroom fruiting bodies for optimal potency and absorption. Products are sold online via doseology.com and e-commerce platforms, as well as through over 360 Canadian retail locations including national chains like Whole Foods Market and select Metro stores, with distribution partnerships expanding reach to more than 12,000 outlets across Canada. Founded in 2019 and headquartered in Kelowna, British Columbia, Canada, Doseology operates primarily in North America, generating revenue from Canada while targeting U.S. consumers. The company pursues diversification into psychedelic and non-psychedelic compounds for mental health therapies, alongside branded functional mushroom lines. In March 2025, Doseology launched Doseology USA Inc., a wholly owned Florida-based subsidiary, to enter the multi-billion-dollar U.S. oral stimulant market and pursue strategic acquisitions for supply chain enhancement; it announced up to $1.9 million in non-brokered private placements to fund growth. In November 2025, Doseology completed extensive North American diligence to secure a strategic manufacturing agreement through its U.S. subsidiary with an FDA-registered, GMP-certified facility specializing in oral pouches for nicotine, caffeine, and nootropics, enabling transition from R&D to commercial production. Recent moves also include appointing Christopher P. Cherry as CFO in May 2024 to support retail expansion and acquisition strategy, alongside reported year-over-year sales growth of 224% while maintaining a debt-free position with cash reserves.
Doseology Announces $2M Financing to Accelerate Commercialization of Oral Stimulant Pouch Platform
Doseology Uplists to OTCQB as DOSEF, Expanding U.S. Investor Access to the Emerging Oral Stimulant Pouch Category
Doseology Launches Feed That Brain® Oral Stimulant Pouches in the U.S. Through Direct-to-Consumer Pilot
Doseology Appoints Larry Latowsky as Executive Chairman of the Board of Directors
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
Doseology Begins Pilot Production of Caffeine-Based Energy Pouches as Feed That Brain® Enters Oral Stimulant Format
2026 Asset Growth: Why Federal Compliance Is the New Metric
The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings
Doseology Files Annual Information Form (AIF), Strengthening Public Disclosure Record AIF Filing Enhances Transparency and Provides Consolidated Disclosure for Investors
Doseology Engages McKinney Regulatory Science Advisors to Advance Innovative Oral Pouch Product Development through Science and Regulatory Expertise
The "New Vice" Economy: 5 Stocks Profiting from the Shift to Clean Fuel
Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.
Doseology Appoints Patrick W. Sills as Strategic Go-to-Market Advisor
Doseology Closes $750,000 Non-Brokered Private Placement
CSE Bulletin: Consolidation - Doseology Sciences Inc. (MOOD)